Publication: APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma
Authors
Rüder, Ulrike ; Denkert, Carsten ; Alisa Kunze, Catarina ; Jank, Paul ; Lindner, Judith ; Jöhrens, Korinna ; Kulbe, Hagen ; Sehouli, Jalid ; Dietel, Manfred ; Braicu, Elena ; Darb Esfahani, Silvia
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-18-050
item.page.type
info:eu-repo/semantics/article
Description
Abstract
APOBEC3 enzymes are part of the innate
immune system and they are important in retroviral
defense. The number of mutations in ovarian cancer
increases with rising levels of APOBEC3B mRNA. We
could confirm that APOBEC3B mRNA is upregulated in
ovarian cancer cell lines and in ovarian cancer tissue. We
evaluated APOBEC3B expression in histologically
defined subtypes of ovarian cancer to identify its
influence on overall survival (OS) and progression-free
survival (PFS).
Tissue microarrays from 219 patients with highgrade serous (HGSC), 61 with low-grade serous
(LGSC), 62 with endometrioid (EC) and 55 with clear
cell (CCC) ovarian carcinoma were stained using an
antibody against APOBEC3B. Real-time quantitative
PCR was performed to detect APOBEC3B mRNA levels
in 274 cases of HGSC, in 11 cases of LGSC, in 47 cases
of EC and in 29 cases of CCC. Tumor-infiltrating
lymphocytes (TILs) have been evaluated in a previous
project.
APOBEC3B staining was cytoplasmic as well as
nuclear and both were positively correlated (P<0.001).
In HGSC a trend was detectable for positive cytoplasmic
staining as favorable regarding OS (P=0.283) and PFS
(P=0.137). High levels of APOBEC3B mRNA were
associated with prolonged PFS in HGSC in univariate
analyses (P=0.043) and multivariate analyses (HR 0.55;
95% CI 0.35-0.88; P=0.012). APOBEC3B cytoplasmic
staining and APOBEC3B mRNA were positively
correlated with TILs.
APOBEC3B in HGSC is related to an active
immune infiltrate. However, there is no evidence for
APOBEC3B as a clinically relevant prognostic
biomarker.
publication.page.subject
Citation
Histology and Histopathology, Vol.34, nº4, (2019)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/